Regulators push openness agenda on raw trial data…and EUPATI issues call for examples of educational materials on medicines development

Yes, that is a long headline is it not?  PharmaTimes and others cover a paper in PloS Medicine authored by a number of medicines regulators including the European Medicines Agency (EMA), calling for openness in raw trial data. The three pronged approach they suggest looks like a good basis for discussion.  It would be interesting … Continue reading Regulators push openness agenda on raw trial data…and EUPATI issues call for examples of educational materials on medicines development